At a glance
| Targets | GIP and GLP-1 receptors |
|---|---|
| Route | Subcutaneous injection |
| Products | Mounjaro; Zepbound |
| Distinct approved use | OSA in adults with obesity |
| Common adverse effects | Gastrointestinal symptoms |
Overview
Mounjaro and Zepbound contain tirzepatide but serve different approved indications. Mounjaro is used for type 2 diabetes, while Zepbound supports long-term weight reduction in eligible adults and treats moderate-to-severe obstructive sleep apnea in adults with obesity. Sleep-apnea approval does not replace an individualized assessment of airway treatment or positive-airway-pressure needs. Trial averages describe groups receiving a manufactured, regulated product with clinical follow-up. They do not predict an individual response or validate mixed research products sold under the same ingredient name.
How it works
Tirzepatide activates glucose-dependent insulinotropic polypeptide and GLP-1 receptors. These pathways influence glucose-dependent insulin secretion, glucagon regulation and food intake. Its fatty-acid side chain supports albumin binding and a prolonged action suitable for weekly administration. Reduced appetite and caloric intake contribute to weight loss; delayed gastric emptying also influences tolerability and absorption of some oral medicines.
How the approved products differ
Zepbound’s current label covers adults with obesity or qualifying overweight, plus moderate-to-severe OSA in adults with obesity. Mounjaro is a diabetes product. Neither indication establishes tirzepatide as a treatment for type 1 diabetes or every cause of fatigue or weight gain.
Weight and sleep-apnea evidence
SURMOUNT-1 found considerably greater weight reduction with tirzepatide than placebo in adults with obesity without diabetes. The FDA’s sleep-apnea approval relied on separate trials measuring apnea-hypopnea events. Weight-loss findings and airway outcomes answer related but different clinical questions.
Major precautions
The label warns about severe gastrointestinal reactions, pancreatitis, gallbladder disease, dehydration-related kidney injury and serious allergy. Hypoglycemia risk rises with insulin or insulin secretagogues. Personal or family medullary thyroid cancer and MEN2 are contraindications; human relevance of the rodent thyroid findings remains uncertain.
Medicines and procedures
Delayed gastric emptying can affect oral medicines. Label-specific precautions apply to oral hormonal contraception during initiation and escalation. Anesthesia teams need to know about use because pulmonary aspiration has been reported with GLP-1 medicines during general anesthesia or deep sedation.
Supporting sources [1]
Interpreting a response
Weight change is only one outcome. Glycemic control, treatment tolerance, nutrition and sleep-apnea symptoms may all influence follow-up. Combining tirzepatide products or adding another GLP-1 receptor agonist is not recommended in Zepbound labeling.
Common questions
Is Zepbound the same treatment as Mounjaro? Both contain tirzepatide, but the brands have different approved clinical uses and product labeling.
Does improvement in weight automatically establish sleep-apnea treatment? The sleep-apnea indication rests on specific studies and applies to adults with obesity and moderate-to-severe obstructive sleep apnea. Other sleep disorders or populations require separate evidence.
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Dual GIP and GLP-1 receptor agonist peptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Zepbound current prescribing information ↗Regulatory source · Checked 2026-10-27
- FDA: Mounjaro prescribing information ↗Regulatory source · Checked 2026-10-27
- Tirzepatide Once Weekly for the Treatment of Obesity. ↗Original research · Checked 2026-10-27
- FDA approves first medication for obstructive sleep apnea ↗Regulatory source · Checked 2026-10-27